Toggle Menu

Press Room

Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial

02/24/2015

Philadelphia, Pa., February 23, 2015, 5:00 PM – Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence...

https://secure.kidneycancer.org/neon/resource/kca/files/ECOG-ACRIN_PressRelease_E2805_renal-cell-trial.pdf

NeonCRM by Neon One